Skip to content

Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up

Simplifying Medical Abortion Provision: Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01150279
Enrollment
1200
Registered
2010-06-24
Start date
2009-08-31
Completion date
Unknown
Last updated
2015-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medical Abortion

Keywords

medical abortion, Medical Abortion Follow Up Care

Brief summary

This study will examine the feasibility, acceptability and usability of a semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit) for at-home follow-up after early medical abortion using mifepristone+misoprostol. The study seeks to: 1. Assess the feasibility of using this test in lieu of standard one-week clinic-based follow up for determination of complete abortion status as part of normal service delivery. In Mexico, follow up will be in two weeks, as is standard care in that . 2. To determine if women using this test at home understand how to use it and can correctly interpret the results; is it practical. 3. Assess women's and provider's acceptability of using at-home pregnancy tests in lieu of clinic-based follow up for confirmation of complete medical abortion in the future.

Interventions

None listed

Sponsors

Stanford University
CollaboratorOTHER
Secretaría de Salud del Distrito Federal
CollaboratorUNKNOWN
Office National de la Famille et de la Population, Tunisia
CollaboratorUNKNOWN
Maternité de la Rabta, Tunisia
CollaboratorUNKNOWN
Clinique du Parc, Tunisia
CollaboratorUNKNOWN
Gynuity Health Projects
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Women age greater than or equal to 18 years * Gestational age less than or equal to 63 days by last menstrual period (LMP), ultrasound or clinical assessment * Agrees to return for follow-up visit and willing to provide an address and/or telephone number for purposes of follow-up * Able to consent to study participation. Inclusion Criteria for Mexico: * Gestational age \<\_ 70 days from LMP * Eligible for mifepristone- misoprostol medical abortion according to clinic guidelines * Willing to follow instructions of the provider regarding use of the at-home pregnancy test * Agrees to provide test results by phone to study coordinator on morning of schedule follow-up visit * Willing to provide an address and/or telephone number for purposes of follow-up * Agrees to return for standard follow-up visit * Wishes to participate in the study * Having easy access to a telephone and transportation * Able to consent to study participation

Exclusion criteria

* Women less than 18 years of age * Women not eligible for medical abortion services * Women unable to provide contact information * Women unable to sign the consent form

Design outcomes

Primary

MeasureTime frame
Percent of women who correctly interpreted their results (in U.S. and Vietnam only)18 months

Secondary

MeasureTime frame
Percent of women who felt confident in using the test and would be willing to use it in place of clinic-based follow up in the future18 months
The proportion of times the provider believes that each participant correctly read her test result18 months
Percent of providers who were comfortable with the urine pregnancy test determining whether women need to return or not for clinic-based follow-up18 months
The proportion of times that the semi-quantitative test correctly identifies all on going pregnancies18 months

Countries

Mexico, Tunisia, United States, Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026